USE OF A CYP3A4 SUBSTRATE DRUG WITH A CYP3A4 SUBSTRATE INHIBITOR

摘要

The present disclosure provides for methods of treating a patient with aCYP3A4 substrate drug contraindicated forconcomitant administration with a strong CYP3A4 inhibitor, wherein the patientis treated with multiple doses of posaconazole, stopsposaconazole treatment, and then is treated with the CYP3A4 substrate drug. Insome embodiments, treatment with the CYP3A4substrate drug is delayed for about 2-21 after stopping posaconazole. In someembodiments, the patient is treated with or prescribed areduced dose of the CYP3A4 substrate drug for about 2-21 after stoppingposaconazole.